Therapeutic Efficacy of Antiglioma Mesenchymal Extracellular Matrix 131I-Radiolabeled Murine Monoclonal Antibody in a Human Glioma Xenograft Model

The development of Mabs, particularly those reactive with primary brain tumors but not with normal brain, provides a potential means of delivering therapeutic agents selectively to human malignant gliomas. Mab 81C6 an IgG2b immunoglobulin, which defines an epitope of the 000 μC i (P = 0.01). The percentage of anhnals with tumor regression progressively increased with increasing doses of isotope. For radiolabeled 45.6, there were 0 of 10 re seen underestimated the dose observed in a directly measured therapeutic trial by 35-52%. In this xenograft model, a radiolabeled antiglioma Mab against the extracelluhir matrix protein temiscin demonstrated therapeutic efficacy. The promising results obtained in this animal model suggest a potential value for this form of therapy against human malignant gliomas. © 1988, American Association for Cancer Research. All rights reserved.

Duke Scholars

Author Michael Rod Zalutsky Radiology

Author Henry Seth Friedman Neurosurgery, Neuro-Oncology

Author Darell Doty Bigner Neurosurgery